Compare PHVS & PFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHVS | PFS |
|---|---|---|
| Founded | 2015 | 1839 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2020 | 2002 |
| Metric | PHVS | PFS |
|---|---|---|
| Price | $34.40 | $24.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $41.82 | $23.75 |
| AVG Volume (30 Days) | 393.4K | ★ 1.0M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 4.28% |
| EPS Growth | N/A | ★ 112.38 |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $73,109,000.00 |
| Revenue This Year | N/A | $0.68 |
| Revenue Next Year | N/A | $5.97 |
| P/E Ratio | ★ N/A | $40.57 |
| Revenue Growth | N/A | ★ 7.06 |
| 52 Week Low | $19.56 | $17.69 |
| 52 Week High | $36.60 | $25.49 |
| Indicator | PHVS | PFS |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 59.31 |
| Support Level | $24.73 | $22.61 |
| Resistance Level | $36.07 | N/A |
| Average True Range (ATR) | 1.53 | 0.48 |
| MACD | -0.09 | 0.07 |
| Stochastic Oscillator | 65.19 | 62.40 |
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.